A Self-Reported Survey-Based Evaluation of the Real-World Effectiveness of Non-mRNA COVID-19 Vaccines During the Second Pandemic Wave in India
Subeikshanan Venkatesan, Amrutha Bindu Nagella, Sukumar Kalvapudi, Akshat Dutt, Karthik Ajith, Varun Muppidi, Varun Anand, Rishab Belavadi, Samiksha Kumar, Venkatesh S Madhugiri

TL;DR
This study surveyed people in India to assess how well non-mRNA vaccines protected against COVID-19 during the second pandemic wave, finding that full vaccination reduced severe disease and mortality.
Contribution
The study provides real-world evidence on the effectiveness of Covishield and Covaxin vaccines in India, highlighting risk factors for breakthrough infections.
Findings
Full vaccination reduced severe disease and mortality compared to incomplete vaccination.
Older age, comorbidities, and healthcare worker status were key risk factors for breakthrough infections.
Covishield and Covaxin had similar breakthrough infection rates, but longer interdose intervals were associated with lower rates.
Abstract
Introduction Breakthrough infections (BIs), defined as SARS-CoV-2 infections occurring in fully vaccinated individuals, provide crucial insights into vaccine effectiveness. Data on BIs after non-mRNA vaccines remains limited. Aim This study aimed to evaluate the incidence, characteristics, and risk factors associated with COVID-19 BIs in individuals vaccinated with Covishield (Serum Institute of India Pvt. Ltd.) and Covaxin (Bharat Biotech) in India. Methods A survey was conducted from June 1 to September 15, 2021, via Google Forms, disseminated through social media and email. After excluding duplicates and incomplete responses, 5248 were analyzed. Statistical analyses, including chi-squared tests and logistic regression, assessed the risk factors for BIs and their severity. Results Among 5248 respondents, 405 (12.9%) reported BIs. Age >60 years was associated with a higher BI…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · COVID-19 epidemiological studies · Vaccine Coverage and Hesitancy
